AMPIO PROVIDES UPDATE ON CONTINUED PROGRESS OF AP-013 PHASE III CLINICAL TRIAL AND MANUFACTURING FACILITY

ENGLEWOOD, Colo., October 10, 2019, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (S...

Learn More

Biodesix Appoints Scott Hutton as Chief Executive Officer

Former CEO David Brunel to Serve as Chairman of the Board of Directors BOULDER, Colo., November 4, 2019 -- Biodesix, Inc., the leader in lung cancer diagnostic solutions, today announced tha...

Learn More

IM Therapeutics Is Developing A Novel Targeted Therapy Pipeline in Autoimmune Disease

Type 1 Diabetes Therapy Being Readied for Clinical Trials; Celiac Disease in Drug Development Autoimmune diseases affect about 4% of the world’s population and comprise over 80 disorders, many of whic...

Learn More

SomaLogic significantly expands key strategic collaboration with Novartis

Ten-year agreement with Novartis demonstrates broad and deep commitment to accelerating disease and therapeutic-specific insights based on proprietary proteomic technology Boulder, Colo., USA — SomaLo...

Learn More

Regulatory Affairs Professionals Society (RAPS) Welcomes New RAPS Colorado Chapter

Rockville, MD, USA, Oct. 17, 2019 (GLOBE NEWSWIRE)  The Regulatory Affairs Professionals Society (RAPS) announced the official launch of the RAPS Colorado Chapter. The group first began as a RAPS...

Learn More

Securisyn Medical Receives FDA 510(k) Clearance for its SolidAIRity™ III Airway Stabilization System

HIGHLANDS RANCH – October 9, 2019 – Securisyn Medical, LLC, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its SolidAIRity™ III Airw...

Learn More

IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures

IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures Funding will Advance Lead Drug in Type 1 Diabetes and Develop HLA-Targeted Therapeutic Platform in Autoimm...

Learn More

AmideBio Awarded SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism

BOULDER, CO, September 30, 2019 – AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Researc...

Learn More

GREFFEX, Inc. Awarded $18.7 Million Contract with NIH to Develop a Plug-and-Play Technology Platform to Expedite Production of Vaccine Candidates for Biodefense and Emerging Infectious Diseases

GREFFEX, Inc. (Aurora, CO), a Fitzsimons Innovation Community company, is a transformative leader in genetic engineering. The company was recently awarded an $18.7 million contract with the National I...

Learn More

Weekly Policy Update: CBSA Submits Comment Letter to CMS Advocating for Patient Access to Timely Precision Diagnostic Information

In July the Centers for Medicare and Medicaid Services (CMS) issued the CY 2020 Hospital Outpatient Prospective Payment System (HOPPS) Proposed Rule, which included concerning proposed revisions to th...

Learn More